

KASIC NEWSLETTER

Issue Eight, Volume One

*Pictured Top: Frankfort, KY
Attribution to The Atlantic*



Norton Infectious Diseases Institute Grand Rounds Educational Series

Every Wednesday
from 12:00 – 12:30 PM EST

[Click here for Grand Rounds
Information](#)

Recently Released Guidelines - Antimicrobial Stewardship Highlights!

[“Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update”](#)

- Expanded discussion on recommendation against routine vancomycin use
- Emphasizes discontinuing post-operative antibiotics

[“Guidelines on the diagnosis and treatment of foot infection in persons with diabetes: IWGDF/IDSA 2023”](#)

- Recommendation on when to cover for *P. aeruginosa*
- Recommendation on durations of therapy in patients with positive bone margins post resection

Time for Testing: National HIV Testing Day is June 27, 2023



Did you know that it's recommended that all adults up to age 64 are tested for HIV at least once in their lifetime, and regularly if they are at risk? Appropriate testing is a key part of ending the HIV epidemic. National HIV Testing Day encourages people to be tested and ensure that they know their HIV status. This year's campaign also encourages anyone who is positive to begin treatment so they can support and maintain their health.

[**Click to know your status by taking the test & the next step**](#)

New Therapeutics for *C. difficile*

The FDA has recently approved a new agent in the management of *C. difficile* infection. Fecal microbiota spores, live-brpk (Vowst) was approved by the FDA in April 2023 and is indicated for the prevention of recurrent *C. difficile* infection. Vowst will accompany previously approved bezlotoxumab (Zinplava) and fecal microbiota, live-jslm (Rebyota) to prevent future episodes of *C. difficile* infection. Whereas bezlotoxumab (Zinplava) is available intravenously and binds *C. difficile* toxin B, Rebyota and Vowst act by reestablishing healthy gut microflora. Vowst is supplied as an oral capsule and Rebyota as a rectal suspension. While the addition of this new agent will expand our therapeutic armamentarium for *C. difficile* infection prevention, antimicrobial stewardship remains a key prevention strategy.